Commentary: The monitoring of adults and children on antiretroviral therapy in the 2013 WHO consolidated ARV guidelines

AIDS

Volumn 28, Issue SUPPL. 2, 2014, Pages

  Essajee, Shaffiq ^a   Kumarasamy, Nagalingeswaran ^b  

^a CLINTON HEALTH ACCESS INITIATIVE   (United States)

^b VHS Medical Centre India   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4+ T LYMPHOCYTE; COST EFFECTIVENESS ANALYSIS; DELAYED DIAGNOSIS; FALSE POSITIVE RESULT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SENSITIVITY AND SPECIFICITY; VIRUS LOAD; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION; FEMALE; HIV INFECTIONS; HUMAN; MALE; PREGNANCY;

ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PREGNANCY;

EID: 84901387721     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000238     Document Type: Note

References (11)

1. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. Recommendations for a public health approach 2006 version. Geneva, Switzerland: World Health Organization; 2006. [Accessed 26 January 2014]
2. UNAIDS. Report on the global AIDS epidemic 2013. Geneva: UNAIDS; 2013. [Accessed 26 January 2014]
3. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-452.
4. Kumarasamy N, Madhavan V, Venkatesh KK, Saravanan S, Kantor R, Balakrishnan P, et al. High frequency of clinically significant mutations following first-line generic HAART failure: implications for second line options in resource-limited settings. Clin Infect Dis 2009; 49:306-309.
5. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
6. Tucker JD, Bien CH, Easterbrook PJ, Doherty MC, Penazzato M, Vitoria M, Peeling RW. Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: a systematic review. AIDS 2014; 28 (Suppl 2):S151-S160.
7. Rutherford GW, Anglemyer A, Easterbrook PJ, Horvath T, Vitoria M, Penazzato M, Doherty MC. Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure. AIDS 2014; 28 (Suppl 2):S161-S169.
8. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2013, www.who.int/hiv/pub/guidelines/arv2013. [Accessed 26 January 2014]
9. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, Wood R. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antiviral Ther 2007; 12:83-88.
10. Kahn JG, Marseille E, Moore D, Bunnell R, Were W, Degerman R, et al. CD4R T-cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. Br Med J 2011; 343:d6884.
11. Loubiere S, Meiners C, Sloan C, Freedberg KA, Yazdanpanah Y. Economic evaluation of ART in resource-limited countries. Curr Opin HIV AIDS 2010; 5:225-231.